Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

McMurray, John J.V., Solomon, Scott D., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S. +30 more·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1911303

Cited by (1,030)

Items 401–500 of 1,030

  1. Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester
    Luca Monzo, Kamil Sedláček, Katarína Hromaníková, Lucie Tomanova, Barry A. Borlaug, Antonı́n Jabor, Josef Kautzner, Vojtěch Melenovský · 2020 · Metabolism
  2. Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
    Jasper Tromp, Piotr P. Ponikowski, Afshin Salsali, Christiane E. Angermann, Jan Biegus, Jon Blatchford, Sean P. Collins, João Pedro Ferreira, Claudia Grauer, Mikhail Kosiborod et al. · 2021 · European Journal of Heart Failure
  3. Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
    Yuze Zhang, Xiaoyan Lin, Yong Chu, Xiaoming Chen, Heng Du, Hailin Zhang, Changsheng Xu, Hong Bo Xie, Qinyun Ruan, Jinxiu Lin et al. · 2021 · Cardiovascular Diabetology
  4. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
    Jonathan W. Cunningham, Muthiah Vaduganathan, Brian Lee Claggett, Ian J. Kulac, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, David L. DeMets, Adrian F. Hernandez, Silvio E. Inzucchi et al. · 2022 · Journal of the American College of Cardiology
  5. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
    Salvatore, Teresa, Galiero, Raffaele, Caturano, Alfredo, Vetrano, Erica, Loffredo, Giuseppe, Rinaldi, Luca, Catalini, Christian, Gjeloshi, Klodian, Albanese, Gaetana, Di Martino, Anna et al. · 2022 · Biomedicines
  6. How to Tackle Therapeutic Inertia in Heart Failure with Reduced Ejection Fraction. A Scientific Statement of the Heart Failure Association of the ESC
    Gianluigi Savarese, Felix Lindberg, Antonio Nicola Cannata, Ovidiu Chioncel, Davide Stolfo, Francesca Musella, Daniela Tomasoni, Magdy Abdelhamid, Debasish Banerjee, Antoni Bayés‐Genís et al. · 2024 · European Journal of Heart Failure
  7. 2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
    Anders Jeppsson, (Co-Chairperson) (Sweden), Bianca Rocca, (Co-Chairperson) (Italy), Emma C. Hansson, (Sweden), Tómas Guðbjartsson, (Iceland), Stefan Karl James, (Sweden) et al. · 2024 · European Journal of Cardio-Thoracic Surgery
  8. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
    Zhang, Yaofu, Jiang, Li, Wang, Junheng, Wang, Tongxin, Chien, Chieh, Huang, Weijun, Fu, Xiaozhe, Xiao, Yonghua, Fu, Qiang, Wang, Shidong et al. · 2022 · Cardiovascular Diabetology
  9. SGLT2-inhibitors; more than just glycosuria and diuresis
    Fathi, Amir, Vickneson, Keeran, Singh, Jagdeep S. · 2021 · Heart Failure Reviews
  10. Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
    Januzzi, James L., Xu, Jialin, Li, JingWei, Shaw, Wayne, Oh, Richard, Pfeifer, Michael, Butler, Javed, Sattar, Naveed, Mahaffey, Kenneth W., Neal, Bruce et al. · 2020 · Journal of the American College of Cardiology
  11. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
    Vishal N. Rao, Evan M. Murray, Javed Butler, Lauren Beth Cooper, Zachary L. Cox, Mona Fiuzat, Jennifer B. Green, JoAnn Lindenfeld, Darren K. McGuire, Michael E. Nassif et al. · 2021 · Journal of the American College of Cardiology
  12. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
    Jun Tang, Lifang Ye, Qiqi Yan, Xin Zhang, Lihong Wang · 2022 · Frontiers in Pharmacology
  13. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
    Paul A. Heidenreich, Biykem Bozkurt, David A. Aguilar, Larry A. Allen, Joni J. Byun, Monica M Colvin, Anita M Deswal, Mark H. Drazner, Shannon M. Dunlay, Linda R. Evers et al. · 2022 · Journal of Cardiac Failure
  14. Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
    David M. Williams, Hannah F Jones, Jeffrey Wayne Stephens · 2022 · Dove Medical Press (Taylor and Francis Group)
  15. Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors
    Milton Packer · 2020 · European Journal of Heart Failure
  16. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
    Ioanna Andreadou, Robert M. Bell, Hans Erik Bøtker, Coert Jozef Zuurbier · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  17. Cardiorenal syndrome: Multi‐organ dysfunction involving the heart, kidney and vasculature
    Feby Savira, Ruth Magaye, Danny Liew, Christopher Michael Reid, Darren J. Kelly, Andrew R. Kompa, S. Jeson Sangaralingham, John C. Jr Burnett, David M. Kaye, Bing Hui Wang · 2020 · British Journal of Pharmacology
  18. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
    Tamique Mason, Otávio R. Coelho‐Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E. Thorpe, Christopher Bonneau, Hwee Teoh, Richard E. Gilbert et al. · 2021 · JACC. Cardiovascular imaging
  19. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years
    Claire Alexandra Lawson, Samuel Seidu, Francesco Zaccardi, Gerry Patrick McCann, Umesh T. Kadam, Melanie Jane Davies, Carolyn S.P. Lam, Hiddo J.L. Heerspink, Kamlesh K. Khunti · 2021 · EClinicalMedicine
  20. Gender-Related Factors in Medication Adherence for Metabolic and Cardiovascular Health
    Vittorio Venditti, Enrico Bleve, Susanna Morano, Tiziana Filardi · 2023 · Metabolites
  21. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure
    Stephen John Greene, Iyanuoluwa Ayodele, Jacob B. Pierce, Muhammad Shahzeb Khan, Sabra C. Lewsey, Clyde W. Yancy, Brooke Alhanti, Harriette G.C. Van Spall, Larry A. Allen, Gregg C. Fonarow · 2024 · JACC Heart Failure
  22. Semaglutide and NT-proBNP in Obesity-Related HFpEF
    Petrie, Mark C., Borlaug, Barry A., Butler, Javed, Davies, Melanie J., Kitzman, Dalane W., Shah, Sanjiv J., Verma, Subodh, Jensen, Thomas Jon, Einfeldt, Mette Nygaard, Liisberg, Karoline et al. · 2024 · Journal of the American College of Cardiology
  23. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis
    Colacci, Michael, Fralick, John, Odutayo, Ayodele, Fralick, Michael · 2022 · Canadian Journal of Diabetes
  24. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Chen, Wen-Jone · 2021 · The Journal of Clinical Endocrinology & Metabolism
  25. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay
    Huan Chen, Da Tran, Hsiu‐Chiung Yang, Sven Nylander, Yochai Birnbaum, Yumei Ye · 2020 · Cardiovascular Drugs and Therapy
  26. Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity
    Yumiko Oishi, Ichiro Manabe · 2020 · Frontiers in Cardiovascular Medicine
  27. SGLT2 inhibitors: the statins of the 21st century
    Eugene Braunwald M. D · 2021 · European Heart Journal
  28. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
    Huitzilihuitl Saucedo‐Orozco, Suzanne N. Voorrips, Salva R. Yurista, Rudolf A. de Boer, Berend Daan Westenbrink · 2022 · Journal of Lipid and Atherosclerosis
  29. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
    Javed Butler, Ciaran J. McMullan, Kevin Joseph Anstrom, Irina Barash, Marc P. Bonaca, Maria Borentain, Stefano Corda, Justin Adrian Ezekowitz, Gary Michael Felker, Davis F. Gates et al. · 2025 · The Lancet
  30. Tissue sodium excess is not hypertonic and reflects extracellular volume expansion
    Rossitto, Giacomo, Mary, Sheon, Chen, Jun Yu, Boder, Philipp, Chew, Khai Syuen, Neves, Karla B., Alves, Rheure L., Montezano, Augusto C., Welsh, Paul, Petrie, Mark C. et al. · 2020 · Nature Communications
  31. Renal dysfunction in cardiovascular diseases and its consequences
    Giacomo Deferrari, Adriano Cipriani, Edoardo La Porta · 2020 · Journal of Nephrology
  32. Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure
    Flávio Araújo Borges, Danúbia Silva dos Santos, Acaris Benetti, Juliano Z. Polidoro, Aline Cavalcantti T. Wisnivesky, Renato O. Crajoinas, Ednei Luiz Antônio, Leonardo Jensen, Bruno Caramelli, Gerhard Malnic et al. · 2021 · Journal of the American Society of Nephrology
  33. Osteopontin in Cardiovascular Diseases
    Kohsuke Shirakawa, Motoaki Sano · 2021 · Biomolecules
  34. Signaling cascades in the failing heart and emerging therapeutic strategies
    Xin He, Tailai Du, Tianxin Long, Xinxue Liao, Yugang Dong, Zhan‐Peng Huang · 2022 · Signal Transduction and Targeted Therapy
  35. Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment
    Riccardo Maria Inciardi, Andrea Bonelli, Tor Biering‐Sørensen, Matteo Cameli, Matteo Pagnesi, Carlo Lombardi, Scott David Solomon, Marco Metra · 2022 · European Journal of Heart Failure
  36. SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study
    Min Xu, Jie Zheng, Tianzhichao Hou, Hong Lin, Tiange Wang, Shuangyuan Wang, Jieli Lu, Zhiyun Zhao, Mian Li, Yu Xu et al. · 2022 · Diabetes Care
  37. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
    Docherty, Kieran F., Jhund, Pardeep S., Anand, Inder, Bengtsson, Olof, Böhm, Michael, de Boer, Rudolf A., DeMets, David L., Desai, Akshay S., Drozdz, Jaroslaw, Howlett, Jonathan et al. · 2020 · Circulation
  38. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
    Mavrakanas, Thomas A., Tsoukas, Michael A., Brophy, James M., Sharma, Abhinav, Gariani, Karim · 2023 · Scientific Reports
  39. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
    Michael Böhm, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Felix Mahfoud, Martina Brueckmann, Waheed Jamal, Anne Pernille Ofstad et al. · 2021 · Journal of the American College of Cardiology
  40. Challenges in developing Geroscience trials
    Yves Rolland, Felipe Sierra, Luigi Ferrucci, Nir Barzilai, Rafael de Cabo, Joan B. Mannick, Anthony A. Oliva, William J. Evans, Davide Angioni, Philipe de Souto Barreto et al. · 2023 · Nature Communications
  41. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
    Lim, Lee-Ling, Chow, Elaine, Chan, Juliana C. N. · 2023 · Nature Reviews Endocrinology
  42. Costs and healthcare utilisation of patients with heart failure in Spain
    Carlos Escobar, Luis F. Varela, Beatriz Palacios, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Roberto Alcázar Arroyo, Nicolás Manito, Manuel Botana · 2020 · BMC Health Services Research
  43. Optimizing Foundational Therapies in Patients With HFrEF
    Abhinav Sharma, Subodh Verma, Deepak L. Bhatt, Kim Alexander Connelly, Elizabeth Swiggum, Muthiah Vaduganathan, Shelley R. Zieroth, Javed Butler · 2022 · JACC Basic to Translational Science
  44. The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer
    Husam Mohamed Abdel-Qadir, Rodrigo A. Carrasco, Peter C. Austin, Yue Chen, Limei Zhou, Jiming Fang, Henry M.H. Su, Iliana Carolina Lega, Padma Kaul, Tomas G. Neilan et al. · 2023 · JACC CardioOncology
  45. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
    Seminer, Allie, Mulihano, Alfredi, O’Brien, Clare, Krewer, Finn, Costello, Maria, Judge, Conor, O’Donnell, Martin, Reddin, Catriona · 2025 · JAMA Neurology
  46. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
    Adeera Levin, Vlado Perkovic, David Collins. Wheeler, Stefan Hantel, Jyothis Thomas George, Maximilian von Eynatten, Audrey Koitka‐Weber, Christoph Wanner, on behalf of the EMPA-REG OUTCOME Investigators · 2020 · Clinical Journal of the American Society of Nephrology
  47. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2
    Qingqing Wu, Qi Yao, Tongtong Hu, Jiabin Yu, Kebing Jiang, Ying Wan, Qizhu Tang · 2023 · Cell Reports Medicine
  48. Human cardiac metabolism
    Marc R. Bornstein, Rong Tian, Zoltan Arany · 2024 · Cell Metabolism
  49. Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization
    Biykem Bozkurt, Gianluigi Savarese, Samuel Adamsson Eryd, Johan Bodegård, John G.F. Cleland, Cindy Khordoc, Takuya Kishi, Marcus Thuresson, Orly Vardeny, Ruiqi Zhang et al. · 2023 · JACC Heart Failure
  50. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients
    Wei‐Ting Chang, Yu‐Wen Lin, Chung‐Han Ho, Zhih‐Cherng Chen, Ping‐Yen Liu, Jhih‐Yuan Shih · 2020 · Archives of Toxicology
  51. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Nicolás Isaza, Paola Calvachi, Inbar Raber, Chia-Liang Liu, Brandon Kyle Bellows, Inmaculada Hernandez, Changyu Shen, Michael C. Gavin, Arthur Reshad Garan, Dhruv S. Kazi · 2021 · JAMA Network Open
  52. Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
    Anna Norhammar, Johan Bodegård, Marc Vanderheyden, Navdeep Tangri, Avraham Karasik, Aldo Pietro Maggioni, Kari Anne Sveen, Tiago Taveira‐Gomes, Manuel Botana, Lukas Hunziker et al. · 2023 · Heart
  53. Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology
    Sherif F. Nagueh · 2020 · Cardiovascular Research
  54. The Upcoming Epidemic of Heart Failure in South Asia
    Pablo Martínez-Amezcua, Waqas Zia Haque, Rohan Khera, Alka M. Kanaya, Naveed A. Sattar, Carolyn S.P. Lam, S Harikrishnan, Sanjiv Jayendra Shah, Namratha R. Kandula, Powell O. Jose et al. · 2020 · Circulation Heart Failure
  55. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
    the BETonMACE Investigators, Stephen James Nicholls, Gregory G. Schwartz, Kevin A. Buhr, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar‐Zadeh, Ewelina Kulikowski, Peter Paul Toth, Norman C.W. Wong et al. · 2021 · Cardiovascular Diabetology
  56. 2020 Clinical practice guidelines for Chronic heart failure
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
  57. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
    William V. Tamborlane, Lori M. Laffel, Naim Shehadeh, ELVIRA M. ISGANAITIS, Michelle Anne Van Name, Jayantha Ratnayake, Cecilia Karlsson, Ensio Norjavaara · 2022 · The Lancet Diabetes & Endocrinology
  58. Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction
    JoAnn M. Lindenfeld, Maria Rosa Costanzo, Michael R. Zile, Anique Ducharme, Richard William Troughton, Alan S. Maisel, Mandeep R. Mehra, Sara C. Paul, Samuel F. Sears, Frank W. Smart et al. · 2024 · Journal of the American College of Cardiology
  59. Out‐of‐Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States
    S. Wang, J. Valero-Elizondo, H. Ali, A. Pandey, M. Cainzos-Achirica, H. Krumholz, K. Nasir, Rohan Khera · 2021 · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
  60. Management of Obesity in Cardiovascular Practice
    Després, Jean-Pierre, Carpentier, André C., Tchernof, André, Neeland, Ian J., Poirier, Paul · 2021 · Journal of the American College of Cardiology
  61. Edema formation in congestive heart failure and the underlying mechanisms
    Zaid A. Abassi, Emad E. Khoury, Tony Karram, Doron Aronson · 2022 · Frontiers in Cardiovascular Medicine
  62. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie Mitchell Ballantyne, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew Jay Budoff, Javed Butler, David Z.I. Cherney et al. · 2024 · Metabolism
  63. Heart failure: assessment of the global economic burden
    Mohammad Darvish, Abdul Shakoor, Lida Feyz, Jeroen Schaap, Nicolas M. Van Mieghem, Rudolf A. de Boer, Jasper Jan Brugts, Robert M. A. van der Boon · 2025 · European Heart Journal
  64. Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
    Victor Okunrintemi, Basem M. Mishriky, James R. Powell, Doyle M. Cummings · 2020 · Diabetes Obesity and Metabolism
  65. SGLT2 Inhibitors and Cardiac Remodelling: A Systematic Review and Meta-Analysis of Randomized Cardiac Magnetic Resonance Imaging Trials
    Nitish K. Dhingra, Nikhil Mistry, Pankaj Puar, Raj Verma, Stefan D. Anker, C. David Mazer, Subodh Verma · 2021 · ESC Heart Failure
  66. Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
    S. Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, Umme Rubab, Prathap Kanagala, Sizheng Steven Zhao, Anne Worthington, Emily E. Brown, Uazman Alam · 2022 · Clinical Therapeutics
  67. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress
    Packer, Milton · 2021 · Cardiovascular Research
  68. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
    Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-Akchar, Mohammad, Deshpande, Radhika, Niaz, Zurain, Kulkarni, Abhishek, Siddique, Momin, Hegde, Shruti · 2022 · JAMA Network Open
  69. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David, Inzucchi, Silvio E., Zinman, Bernard, Wanner, Christoph, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Ofstad, Anne Pernille, Salsali, Afshin, George, Jyothis T. et al. · 2021 · ESC Heart Failure
  70. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial
    Zachary L. Cox, Sean P. Collins, Mark F. Aaron, Gabriel Antonio Hernandez, A. Thomas McRae, Beth Towery Davidson, M. J. Fowler, Christopher John Lindsell, Frank E. Harrell, Cathy A. Jenkins et al. · 2020 · American Heart Journal
  71. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
    Francesco Giorgino, Jiten P Vora, Peter Fenici, Anna Solini · 2020 · Cardiovascular Diabetology
  72. Advanced Heart Failure: Guideline-Directed Medical Therapy, Diuretics, Inotropes, and Palliative Care
    Daniela Tomasoni, Julie K.K. Vishram‐Nielsen, Matteo Pagnesi, Marianna Adamo, Carlo Lombardi, Finn Gustafsson, Marco Metra · 2022 · ESC Heart Failure
  73. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
    Hongyan Liu, Vikas S. Sridhar, Jacinthe Boulet, Atit Dharia, Abid Ali Khan, Patrick R. Lawler, David Z.I. Cherney · 2021 · Metabolism
  74. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
    Mona Fiuzat, CARINE E. HAMO, Javed Butler, William T. Abraham, Ersilia M. DeFilippis, Gregg C. Fonarow, JoAnn M. Lindenfeld, Robert John Mentz, Mitchell A. Psotka, Scott David Solomon et al. · 2022 · Journal of the American College of Cardiology
  75. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
    Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, Luca Bergamaschi, Emanuele Gallinoro, Celestino Sardu, Niya Boykova Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti et al. · 2022 · Frontiers in Cardiovascular Medicine
  76. ACC/AHA/HFSA 2022 and ESC 2021 Guidelines on Heart Failure Comparison
    Amir Hossein Behnoush, Amirmohammad Khalaji, Nasim Naderi, Haleh Ashraf, Stephan von Haehling · 2022 · ESC Heart Failure
  77. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
    Min Zhao, Shusen Sun, Zhenguang Huang, Tiansheng Wang, Huilin Tang · 2020 · Clinical Journal of the American Society of Nephrology
  78. Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus
    Amelia S. Wallace, Alex R. Chang, Jung‐Im Shin, Jodie A. Reider, Justin Basile Echouffo-Tcheugui, Morgan Erika Grams, Elizabeth Selvin · 2022 · The Journal of Clinical Endocrinology & Metabolism
  79. Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
    ELENA YU. RYKOVA, Vadim Valer'evich Klimontov, Elena O Shmakova, Anton Ivanovich Korbut, Tatyana I Merkulova, Julia G. Kzhyshkowska · 2025 · International Journal of Molecular Sciences
  80. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
    Stefano Romeo, Antonio Vidal‐Puig, Mansoor Husain, Rexford S. Ahima, Marcello Arca, Deepak L. Bhatt, Anna Mae Diehl, Luigi Fontana, Roger Foo, Gema Frühbeck et al. · 2025 · European Heart Journal
  81. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lorenzo Gubian, Angelo Avogaro, Gian Paolo Fadini · 2020 · BMJ Open Diabetes Research & Care
  82. Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments
    Kazuomi Kario, Bryan Williams · 2021 · Hypertension
  83. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
    Jawad H. Butt, Kieran F. Docherty, Pardeep S. Jhund, Rudolf A. de Boer, Michael Böhm, Akshay Suvas Desai, Jonathan G. Howlett, Silvio E. Inzucchi, Mikhail Kosiborod, Felipe A. Martínez et al. · 2021 · European Journal of Heart Failure
  84. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐ Reduced
    João Pedro Ferreira, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Tomoko Iwata, Afshin Salsali, Cordula Zeller, Stuart Pocock, Faiez M. Zannad, Milton Packer · 2021 · European Journal of Heart Failure
  85. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
    Husam M. Salah, Subhi Jamal Alaref, Muhammad Shahzeb Khan, Malek Al‐Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, John Paul Mounsey, Stephen John Greene, Darren K. McGuire, Renato D. Lópes et al. · 2022 · Cardiovascular Diabetology
  86. Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
    Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik · 2022 · International Journal of Molecular Sciences
  87. The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
    Katharina Andrea Schuett, Nikolaus Marx, Michael Lehrke · 2023 · Circulation Research
  88. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease
    Heng‐Chih Pan, Jui‐Yi Chen, Hsing‐Yu Chen, Fang-Yu Yeh, Thomas Tao-Min Huang, Chiao‐Yin Sun, Shiow‐Ing Wang, James Cheng‐Chung Wei, Vin‐Cent Wu · 2024 · JAMA Network Open
  89. Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
    Edoardo Gronda, Mariell L Jessup, Massimo Iacoviello, Alberto Palazzuoli, Claudio Napoli A · 2020 · Journal of the American Heart Association
  90. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure
    Shunsuke Tamaki, Takahisa Yamada, Tetsuya Watanabe, Takashi Morita, Yoshio Furukawa, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Makoto Abe et al. · 2021 · Circulation Heart Failure
  91. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
    Min Zhuo, Julie M. Paik, Deborah J. Wexler, Joseph Vincent Bonventre, Seoyoung C. Kim, Elisabetta Patorno · 2021 · American Journal of Kidney Diseases
  92. Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions
    Mengxi Yang, Di Sun, Yu Wang, Mengwen Yan, Jingang Zheng, Jingyi Ren · 2022 · Frontiers in Cardiovascular Medicine
  93. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Rujie Zheng, Yue Wang, Junnan Tang, Jie-Ying Duan, Ming-Yue Yuan, Jinying Zhang · 2022 · PubMed Central
  94. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
    Adriaan A. Voors, Kevin Damman, John R. Teerlink, Christiane E. Angermann, Sean P. Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka et al. · 2022 · European Journal of Heart Failure
  95. Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com Cardiomiopatia da Doença de Chagas – 2023
    José Antônio Marin‐Neto, Anis Rassi, Gláucia Maria Moraes de Oliveira, Luís Cláudio Lemos Correia, Alberto Novaes Ramos, Alejandro O. Luquetti, Alejandro Marcel Hasslocher‐Moreno, Andréa Silvestre de Sousa, Ângelo Amato Vincenzo de Paola, Antônio Carlos Sobral Sousa et al. · 2023 · Arquivos Brasileiros de Cardiologia
  96. <scp>Sodium‐glucose co‐transporter‐2</scp> inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
    Neuen, Brendon L., Arnott, Clare, Perkovic, Vlado, Figtree, Gemma, de Zeeuw, Dick, Fulcher, Greg, Jun, Min, Jardine, Meg J., Zoungas, Sophia, Pollock, Carol et al. · 2021 · Diabetes, Obesity and Metabolism
  97. Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
    Alexandros Kasiakogias, Enrico Agabiti Rosei, Miguel Camafort, Georg Ehret, Luca Faconti, João Pedro Ferreira, Jana Brguljan-Hitij, Andrzej Januszewicz, Thomas Kahan, Athanasios John Manolis et al. · 2021 · Journal of Hypertension
  98. Towards precision medicine in heart failure
    Chad S. Weldy, Euan Angus Ashley · 2021 · Nature Reviews Cardiology
  99. Primary and Secondary Outcome Reporting in Randomized Trials
    Stuart Pocock, Xavier Rosselló, Ruth Owen, Timothy John Collier, Gregg W. Stone, Frank W. Rockhold · 2021 · Journal of the American College of Cardiology
  100. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial
    Kristoffer Berg Hansen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, Bertil Thyrsted Ladefoged, Mads Jønsson Andersen, Steen Hvitfeldt Poulsen, Barry A. Borlaug, Roni Ranghoej Nielsen, Niels Møller, Henrik Wiggers · 2024 · Circulation